OriCAR-017 for Lymphoproliferative Disorders

"Individuals eligible for this research study must exhibit lymphoproliferative disorders and fall within the age bracket of 18 to 75. The trial aims to enroll approximately 81 candidates."

"As per the details on clinicaltrials.gov, this particular study is not presently seeking new participants. Its initial posting was on April 15, 2024, with the latest update done a day prior to that deadline. Despite this trial being closed for recruitment, it's worth noting that there are currently 4062 other trials actively accepting patients for enrollment."

"The objective of this investigation, to be evaluated within a period extending up to 28 days, is focused on identifying dose-limiting toxicity (DLT). Additional endpoints consist of Progress-Free Survival (PFS) in subjects with RR/MM as per the IMWG Criteria by Local Investigators, Evaluation of MRD negative Rate through flow cytometry for patients showing MRD negativity status, and Assessment of Disease Control Rate (DCR) defined as the ratio of individuals exhibiting CBR (Clinical Benefit Rate) + Stable Disease based on evaluations by Local Investigator following IMWG Criteria."

"Patient eligibility for this research demands individuals between the ages of 18 and 75. Notably, there are a total of 444 investigations focused on minors under 18 years old and 3750 studies targeting participants over 65 years old."

"Our assessment at Power rates the safety of OriCAR-017 as a 1 on our scale. This is due to its Phase 1 trial status, indicating only preliminary data supporting both safety and efficacy."